[Potential of personalized antihypertensive therapy].
The trend of genetic investigation in cardiovascular disease is toward use of genome wide association (GWA) study. Even though several SNPs had been confirmed as a certain risk of myocardial infarction or diabetes mellitus, GWA study of hypertension did not come up with a final answer. A feasible reason is less effect of each SNP in the genetic predisposition to hypertension. Another reason is that the morbidity of hypertension is inappropriate target to assess the genetic contribution. A solution might be to introduce a genetic epidemiological or pharmacogenomic approach. Indeed, recent investigations revealed that several SNPs are involved in salt sensitivity or the efficacy of antihypertensive treatment. In this review, we would like to discuss the potential of personalized antihypertensive therapy.